Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of August 31st – September 6th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view full article.

10. Red White & Bloom Posts Q2 2020 Earnings, Firms Up Platinum Vape Acquisition

RWB Posted Q2 Adjusted EBITDA of $6.5 Million, Which Excluded the Financials of Both of RWB’s Pending Major Acquisitions

Platinum Vape boasts current annualized revenues of over $102 million and EBITDA of approximately 25%-30% and the deal is slated to close on or around September 15, 2020. In addition to Platinum Vape, Red White & Bloom’s RWBYF acquisition of PharmaCo, a dominant Cannabis operator and leader in the burgeoning Michigan market, is also nearing its completion and will Follow Regulatory Approval from the State.

READ FULL RWB ARTICLE

9. Interview with Havn Life Sciences Director and Former Aphria CEO Vic Neufeld

Prior to His Running Leading Canadian LP Aphria, Neufeld Served as President and CEO of Jamieson Wellness for 21 Years

Q: You were on the ground floor of scaling up one of the largest Cannabis companies on the planet. What similarities do you see from the early days of that opportunity and where things are at now within Psychedelics?

READ FULL VIC NEUFELD ARTICLE

8. Psychedelic Company Compass Pathways Files to Go Public

The UK-based Mental Health Company Known for its Psychedelic Treatments, Has Filed to Go Public This Week

Compass Pathways, which has raised $116 million so far, said it plans to list its American depositary shares on the NASDAQ under the ticker “CMPS”.

READ FULL COMPASS PATHWAYS ARTICLE

7. U.S. Cannabis Execs Say the Industry is Heading for a Turnaround

They Predicted That a Biden Win and a Democrat Controlled Senate Would Pour ‘Jet Fuel’ on the American Cannabis Industry

I spoke with the top executives of 7 of the biggest U.S. Cannabis Stocks, including Green Thumb GTBIFCuraleaf CURLF, and Trulieve TCNNF, to understand what’s in store for the industry after a disappointing 2019 and a challenging start to 2020.

READ FULL CANNABIS EXECS ARTICLE

6. Psychedelic Company Numinus Files $4 Million Offering

Numinus is Creating an Ecosystem of Health Solutions Centred on Developing and Supporting the Safe, Evidence-Based, Accessible Use of Psychedelic-Assisted Therapies

Numinus Wellness LKYSD has filed a final short form prospectus to offers up to 16,000,000 units at a price of $0.25 per unit for gross proceeds of up to $4 million. The company said it would use the net proceeds of the offering for MDMA and Psilocybin compassionate access protocol implementation, to make these drugs accessible to specific patient groups before they are available on the market.

READ FULL NUMINUS ARTICLE

5. Cowen & Co Issues U.S. Cannabis Update, Remains Bullish on Green Thumb, Cresco, Curaleaf

Cowen’s Top Pick for the U.S. Cannabis Space is Green Thumb Industries

On the first of the month, Cowen and Co sent out an industry update specifically for the multi-state operators (MSOs), which analyst Vivien Azer headlines “MSO Earnings review adds to our conviction on U.S. operators.” Azer reiterates Cowen’s Outperform rating on Green Thumb GTBIFCresco Labs CRLBF, and Curaleaf CURLF within the report.

READ FULL U.S. CANNABIS ARTICLE

4. Revive Therapeutics Set to Collaborate with the University of Wisconsin System on Psilocybin Clinical Trial

The Trial is for the Potential Treatment of Methamphetamine Use Disorder

Revive Therapeutics RVVTF said it has stuck a clinical trial agreement (CTA) with the University of Wisconsin System (UWS) to advance its Psilocybin therapy for the potential treatment of methamphetamine use disorder.

READ FULL REVIVE THERAPEUTICS ARTICLE

3. Trulieve Cannabis Can Go higher Still, M Partners Says

Trulieve’s Share Price Has Risen Sharply Over the Past Month and This Analyst Sees More Upside From Here

First out of the gate with edible Cannabis products in the state of FloridaTrulieve TCNNF is likely to capture a market leadership position in Edibles, just like it has done with dried flower.

READ FULL TRULIEVE ARTICLE

2. Drug Development Company to Launch First LSD-MDMA Combination Clinical Trial

As Anyone Who Has Been to Shakedown Street Knows, the Drug Cocktail of LSD and MDMA is Referred to as “Candyflipping”

But for JR Rahn, the founder and co-CEO of Psychedelic drug development startup MindMed MMEDF, the combination, along with therapy, could become an FDA-approved treatment for certain mental illnesses one day.

READ FULL MINDMED ARTICLE

1. Historic Day as Trulieve Introduces Edibles in Florida and Serves its First Patient

The Tallahassee Store That Saw the First Medical Marijuana and Smokable Flower Sales Serves Long-Time Truliever with First Edible Sale in the State of Florida

Trulieve TCNNF announced that it began offering edible cannabis products to patients in Florida following finalized regulations from the Florida Department of Health for the sale of edible cannabis products and approval of its products. Trulieve received approval for its first line of edibles in its medical cannabis dispensaries across the state, expanding patient access to the types of products they have been requesting for years.

READ FULL TRULIEVE ARTICLE

Photo by Esteban Lopez on Unsplash

BENZINGA CANNABIS CONFERENCE

Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us September 13-14, 2022 at The Palmer House in Chicago, IL.

Posted In: cannabis industryThe Cannabis InvestorTrulieveCannabisEarningsNewsPenny StocksMarketsGeneral